We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+8.21%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$214M
AUM Growth
+$9.71M
Cap. Flow
-$616K
Cap. Flow %
-0.29%
Top 10 Hldgs %
6.68%
Holding
490
New
42
Increased
186
Reduced
165
Closed
36

Top Buys

Rank Stock Value
1
OCCI
OFS Credit Co
OCCI
+$2.05M
2
HYG icon
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
+$1.92M
3
ECC
Eagle Point Credit Company
ECC
+$1.26M
4
APP icon
Applovin
APP
+$1.04M
5
CEG icon
Constellation Energy
CEG
+$1.01M

Top Sells

Rank Stock Value
1
OXLC
Oxford Lane Capital
OXLC
+$1.49M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$1.06M
3
GEN icon
Gen Digital
GEN
+$1.01M
4
ADBE icon
Adobe
ADBE
+$989K
5
STE icon
Steris
STE
+$907K

Sector Composition

Rank Sector Weight
1 Financials 28.16%
2 Healthcare 18.37%
3 Technology 14.33%
4 Industrials 8.16%
5 Consumer Discretionary 6.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LGND icon
201
Ligand Pharmaceuticals
LGND
$5.96B
$405K 0.19%
4,049
– –
ZLAB icon
202
Zai Lab
ZLAB
$2.1B
$404K 0.19%
16,727
– –
BCRX icon
203
BioCryst Pharmaceuticals
BCRX
$2.43B
$402K 0.19%
52,865
– –
INSM icon
204
Insmed
INSM
$22.7B
$390K 0.18%
5,344
– –
EXEL icon
205
Exelixis
EXEL
$14B
$389K 0.18%
14,998
– –
RYTM icon
206
Rhythm Pharmaceuticals
RYTM
$7.28B
$389K 0.18%
7,423
– –
ASND icon
207
Ascendis Pharma A/S
ASND
$16.6B
$385K 0.18%
2,576
– –
HALO icon
208
Halozyme
HALO
$9.66B
$380K 0.18%
6,637
– –
LEGN icon
209
Legend Biotech
LEGN
$3.73B
$368K 0.17%
7,542
– –
IOVA icon
210
Iovance Biotherapeutics
IOVA
$2.19B
$367K 0.17%
39,069
– –
YMAB
211
DELISTED
Y-mAbs Therapeutics
YMAB
$359K 0.17%
27,332
– –
AMGN icon
212
Amgen
AMGN
$203B
$355K 0.17%
1,103
– –
DAWN
213
DELISTED
Day One Biopharmaceuticals
DAWN
$355K 0.17%
25,491
– –
ITCI
214
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$352K 0.16%
4,814
– –
ROIV icon
215
Roivant Sciences
ROIV
$25B
$352K 0.16%
30,467
– –
ARDX icon
216
Ardelyx
ARDX
$1.25B
$350K 0.16%
50,747
– –
INCY icon
217
Incyte
INCY
$23.7B
$347K 0.16%
5,254
– –
REGN icon
218
Regeneron Pharmaceuticals
REGN
$69.9B
$337K 0.16%
321
-954
-75% -$1.06M
ACAD icon
219
Acadia Pharmaceuticals
ACAD
$4.35B
$336K 0.16%
21,826
– –
PTCT icon
220
PTC Therapeutics
PTCT
$6.29B
$331K 0.15%
8,925
– –
FOLD
221
DELISTED
Amicus Therapeutics
FOLD
$330K 0.15%
30,939
– –
SRPT icon
222
Sarepta Therapeutics
SRPT
$1.68B
$329K 0.15%
2,635
– –
KRYS icon
223
Krystal Biotech
KRYS
$10.4B
$328K 0.15%
1,802
– –
TARS icon
224
Tarsus Pharmaceuticals
TARS
$2.62B
$327K 0.15%
9,938
– –
IONS icon
225
Ionis Pharmaceuticals
IONS
$9.25B
$321K 0.15%
8,009
– –
7 8
9
10 11

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
ALS
Andrew L. Share $214M AUM 14.75% 1-Year Est. Return

Virtus ETF Advisers's Q3 2024 Portfolio in Review

As of Q3 2024, Virtus ETF Advisers held 490 positions worth $214M, up 4.8% from $204M the previous quarter. Its ten largest holdings account for 6.7% of the portfolio.

Virtus ETF Advisers's Q3 2024 filing shows 42 new, 186 increased, 165 reduced and 36 closed positions. Its largest new stake was OFS Credit Co: 278,579 shares worth $2.06M. The largest sale was Oxford Lane Capital, an estimated $1.49M.

By sector, the portfolio is most concentrated in Financials at 28% of assets, up from 27% a quarter earlier, followed by Healthcare and Technology.

  • Virtus ETF Advisers's largest Q3 2024 buy was OFS Credit Co: 278,579 shares worth $2.06M.
  • Virtus ETF Advisers added most to Public Storage in Q3 2024, an estimated $927K increase.
  • Virtus ETF Advisers's biggest Q3 2024 reduction was Regeneron Pharmaceuticals, cutting an estimated $1.06M.
  • Virtus ETF Advisers fully exited Oxford Lane Capital in Q3 2024, selling an estimated $1.49M.
  • Virtus ETF Advisers's ten largest holdings make up 6.7% of its $214M portfolio in Q3 2024.
  • Virtus ETF Advisers opened 42 new positions and closed 36 in Q3 2024.
  • Virtus ETF Advisers's portfolio value rose 4.8% quarter-over-quarter to $214M.

Based on Virtus ETF Advisers's 13F filing for Q3 2024, filed 14 Nov 2024.